FDA To Review Pfizer’s Abrilada For Humira Interchangeability
Adalimumab Biosimilar Is Set For US Launch In July 2023
The US FDA is reviewing Pfizer’s Humira biosimilar, Abrilada, to assess whether the compound can be granted an interchangeability designation with the original drug.
You may also be interested in...
FDA decision ends Boehringer Ingelheim’s exclusivity for interchangeable biosimilar of Humira after just a few months. Pfizer reveals pricing and launch information for its Abrilada version of adalimumab.
An FDA decision around the timing of first interchangeable biosimilar exclusivity has brought to an end Boehringer Ingelheim’s time on the market with a unique interchangeable Humira rival, with the agency also granting interchangeability for Pfizer’s Abrilada version of adalimumab.
Following Amgen’s debut of the first US Humira rival earlier this year, as many as eight further FDA-approved adalimumab biosimilars are about to launch. Generics Bulletin breaks down all the different players and how they are positioning themselves in such a competitive market.